Medicamen Biotech Ltd

Shareholding / Insider Disclosure

• Director Sanjay Bansal divested 32,813 equity shares (0.76% to 0.51%).
• Post-disposal holding stands at 70,000 shares.
• Trading was on-market for a value of Rs 1,05,42,440.
• Date of intimation: 30.09.2026.
• Period of trading: 28.09.2026 to 30.09.2026.
• Mode: On market.

AGM approvals

• To receive, consider and adopt the Audited Standalone Financial Statements for year ended 31 March 2026 and reports.
• To receive, consider and adopt Audited Consolidated Financial Statements for year ended 31 March 2026.
• Final dividend on equity shares for the year ended March 31, 2026.

Governance actions

• Re-appoint Suresh Kumar Singh as Director liable to retire by rotation.
• Re-appoint Sanjay Bansal as Director liable to retire by rotation.
• Ratify remuneration of Cost Auditors for FY ending March 31, 2027.

Related party approvals

• Approve material related party transactions with Shivalik Rasayan Limited.
• Approve material related party transactions with Medicamen Life Sciences Private Limited.

Medicamen Biotech Limited — Trading Window closed from Oct 01, 2026 till 48 hours after the announcement of the Financial Results for the quarter and half year ending September 30, 2026

AGM Details

• AGM held on 26 September 2026 at 12:00 PM IST via two-way VC/OAVM.
• Remote e-voting cut-off date: 19 September 2026.
• E-voting window: 23-25 September 2026; voting during AGM also permitted.
• Meeting concluded at 12:45 PM IST.
• Scrutinizer appointed: M/s AMJ & Associates.

Resolutions Put to Vote

• Item 1: Ordinary – adopt standalone financial statements for year ended 31 March 2026.
• Item 2: Ordinary – adopt consolidated financial statements for year ended 31 March 2026.
• Item 3: Ordinary – declare dividend on equity shares.
• Item 4: Ordinary – re-appoint Suresh Kumar Singh as director liable to retire by rotation.
• Item 5: Ordinary – re-appoint Sanjay Bansal as director liable to retire by rotation.
• Item 6: Ordinary – ratify remuneration of Cost Auditors.
• Item 7: Ordinary – approve material related party transactions with Shivalik Rasayan Limited.
• Item 8: Ordinary – approve material related party transactions with Medicamen Life Sciences Private Limited.

Voting Status & Observations

• Voting results to be declared and posted on the company's website and RTA.
• Results communicated to stock exchanges.

Financial performance

• Standalone revenue from operations: 17,884.58 Lakhs, up 18.08% YoY.
• Consolidated revenue: 19,776.97 Lakhs, up 21.66% YoY.
• Standalone EBITDA: 2,139.10 Lakhs, down from 2,278.20 Lakhs.
• Consolidated EBITDA: 2,270.03 Lakhs, up 12.92%.
• Standalone PAT: 940.87 Lakhs.
• Consolidated PAT: 979.64 Lakhs, up 49.43%.
• Standalone EPS: 6.94; Consolidated EPS: 7.22.
• Dividend: Final dividend of Rs 1 per share, subject to AGM approval.
• Market cap: ₹302.86 Crore as of 31 Mar 2026.

Capital structure & capital allocation

• Authorised share capital: ₹15 Crore; Issued & paid-up: ₹13.56 Crore.
• Preferential issue: 8.48 lakh equity shares at ₹530; 6.50 lakh warrants issued.
• Funds raised utilised as disclosed; no deviation from offer documents.

Domestic business & Lifesciences

• Medicamen Lifesciences grew 71% year-on-year; present in 9 states with 112 professionals.
• Network includes 1,800+ KOLs/KBLs, 8,000+ doctors, 10,000 retail counters, 225+ distributors.
• Focused on cardiovascular and diabetes therapies; growing domestic brand business.

International, CDMO and regulatory

• Denmark and Norway product registrations; regulatory dossiers for oncology injectable/OSD lines.
• Two complex oncology CDMO projects completed for a US company.
• EU-GMP facilities; USFDA-approved facility; expanding CDMO partnerships.

Manufacturing, product portfolio & quality

• Three manufacturing plants: Bhiwadi (EU-GMP), Haridwar I (WHO-GMP/FDA Ethiopia), Haridwar II (USFDA).
• Product portfolio spans oncology, cardiovascular, diabetes, nutraceuticals, other formulations.
• In-house R&D and analytical capabilities; focus on complex generics.

Governance, risk management & controls

• Board of 10 directors; two Independent Directors joined Aug 12, 2025; Ashwani Sharma redesignated as Whole-Time Director.
• NRC reconstituted Feb 13, 2026; several board/committee changes during FY2025-26.
• Auditors: Rai Qimat & Associates; Internal: Cheena & Associates; Cost: SPB & Co.

ESG, CSR & environmental sustainability

• CSR spend: ₹25.20 Lakhs; unspent ₹6.13 Lakhs to be transferred to Schedule VII funds.
• Energy: total consumption 31,30,53,69,500 kJ; water withdrawal 24,828.579 KL.
• ETP-based waste management; Zero Liquid Discharge target; 99.69% dematerialisation of equity.

Related party transactions & governance flags

• Material RPT with Shivalik Rasayan Limited (holding company): APIs, RD, services; cap up to ₹30 Cr.
• Actual RPT with SRL in 2025-26: ₹1,352.89 Lakhs; related-party approvals; arm's length pricing.
• MLSPL (subsidiary): sale of products ₹184.59 Lakhs; advances ₹280 Lakhs; AR ₹150.84 Lakhs.

Outlook & risks

• Positive industry backdrop; growth driven by regulated markets, CDMO, and domestic branded formulations.
• Focus on manufacturing efficiency, regulatory discipline, and capacity utilisation to sustain momentum.

Filing context

• BRRS for FY2025-26 submitted; forms part of Integrated Annual Report to stock exchanges.

CSR highlights

• CSR 2025-26: Rs 25.20 lakh spent; Rs 31.33 lakh requirement; Rs 6.13 lakh unspent; Education/Health.

BR governance

• Chairman Rahul Bishnoi is BR head; DIN 00317960.

Subsidiaries

• Subsidiaries: OPAL Pharmaceuticals Pty Ltd (100%), Medicamen Life Sciences Pvt Ltd (60%), Shivalik Rasayan Ltd (40.46%).

ESG energy

• Energy: total consumption 31,305,369,500 kJ; intensity 0.004861 kWh per rupee turnover.

ESG water

• Water: groundwater withdrawal 24,828.579 KL; ETP; ZLD target.

Regulatory compliance

• NSE non-compliance notice; Rs 7,080; payment completed.

Related party transactions

• RPTs: purchases from related parties 11.86%; loans 47.58%; investments 100%.

Board composition

• Board: 9 directors; 2 women; KMP female 1 of 4.

Stakeholder complaints

• No material complaints; Whistle Blower policy; POSH committees functioning.

Dividend record date and book closure

• Purpose: determine entitlement to the Final Dividend for FY2025-26 at the 33rd AGM.
• Security: equity shares.
• Book closure: Sep 20–26, 2026 (both days inclusive).
• Record date: Sep 19, 2026 for dividend payment.
• Dividend: final dividend recommended by board, subject to shareholder approval.
• Payment timeline: payment to shareholders on record date, subject to applicable laws.

Dividend and meeting dates

• Final dividend of 10% (Re 1 per equity share) subject to shareholder approval.
• Register and transfer books closed Sept 19–25, 2026 for dividend entitlement.
• e-voting window Sept 23–25, 2026; AGM on Sept 26, 2026 via VC/OAVM.